Our pipeline

Target/Product

Indication(s)

Research

Preclinical Development

Clinical Development – Phase 1/2

Targeted Milestones

Porcupine Inhibitor
(RXC004)

Monotherapy in solid tumours
(genetically selected MSS mCRC and pancreatic cancer; biliary cancer)

Combination with anti-PD-(L)1
(genetically selected MSS mCRC)

Phase 1 mono safety
completion – H1 2021

Phase 2 start H1 2021

Read more

RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. Aberrant Wnt signalling contributes directly to tumour growth and plays an important role in immune resistance to treatment with immuno-oncology agents such as…

ROCK2
Selective Inhibitor
(RXC007)

Lung fibrosis (IPF)
Liver fibrosis (NASH)

Entering clinic – H1 2021

Read more

RXC007 is an orally available, highly selective small molecule inhibitor that targets Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signalling pathway, believed to be central to fibrosis. ROCK2 is therefore an important emerging drug target and RXC007 has the potential to…

GI-targeted ROCK inhibitor

Fibrosis associated with
Crohn’s disease

Preclinical development
candidate – H1 2021

Read more

Our GI-targeted ROCK inhibitor is a first-in-class programme designed to treat Crohn’s Disease-associated fibrosis. Up to 50% of patients with Crohn’s disease can develop significant fibrosis and stricture formation within 10 years after diagnosis. The current management of fibrotic strictures of the gastrointestinal (GI) tract is primarily surgical…

Research Targets

Oncology and Fibrosis

In-house Research Teams investigating oncology and fibrosis targets

Read more Read more

Our research strategy in fibrosis builds on our proven drug discovery capability, exemplified by the in-house discovery of our selective ROCK2 inhibitor RXC007, which we are progressing to the clinic.

Our research strategy in oncology builds on our proven in-house drug discovery capability, which has successfully discovered two clinical stage oncology small molecules RXC004 and RXC005 (now LOXO-305, Loxo Oncology/Eli Lilly), as well as concluding three oncology deals to date.

Porcupine Inhibitor
(RXC006)

Lung fibrosis (IPF)

Licensed to AstraZeneca

Read more

In August 2020, Redx Pharma signed a significant out licensing agreement for our porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF). Under the terms of the exclusive global…

Pan-RAF Inhibitor

Oncology

Asset sale to Jazz Pharmaceuticals

Read more

Pan-RAF inhibitor sold to Jazz Pharmaceuticals, Pan-RAF inhibitor programme aims to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs. Mutations leading to uncontrolled signalling via the RAS-RAF-MAPK pathway are seen in over one third of all cancers. The RAF kinases (A-RAF, B-RAF and C-RAF) are an integral part of this pathway, with B-RAF mutations commonly seen…

Redx development

Research

Partnered programme

MSS mCRC=Microsatellite-Stable Metastatic Colorectal Cancer; IPF-Idiopathic Pulmonary Fibrosis; NASH-Non-alcoholic Steatohepatitis